JP2023523706A - アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法 - Google Patents

アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法 Download PDF

Info

Publication number
JP2023523706A
JP2023523706A JP2022563366A JP2022563366A JP2023523706A JP 2023523706 A JP2023523706 A JP 2023523706A JP 2022563366 A JP2022563366 A JP 2022563366A JP 2022563366 A JP2022563366 A JP 2022563366A JP 2023523706 A JP2023523706 A JP 2023523706A
Authority
JP
Japan
Prior art keywords
patient
patients
disease
fasudil
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523706A5 (https=
Inventor
マカリスター，トーマス
ジェイコブソン，スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of JP2023523706A publication Critical patent/JP2023523706A/ja
Publication of JP2023523706A5 publication Critical patent/JP2023523706A5/ja
Priority to JP2025282162A priority Critical patent/JP2026053635A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022563366A 2020-04-23 2021-01-08 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法 Pending JP2023523706A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025282162A JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014272P 2020-04-23 2020-04-23
US63/014,272 2020-04-23
PCT/US2021/012588 WO2021216139A1 (en) 2020-04-23 2021-01-08 Methods of using rho kinase inhibitors to treat alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025282162A Division JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法

Publications (2)

Publication Number Publication Date
JP2023523706A true JP2023523706A (ja) 2023-06-07
JP2023523706A5 JP2023523706A5 (https=) 2024-01-11

Family

ID=78269840

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563366A Pending JP2023523706A (ja) 2020-04-23 2021-01-08 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法
JP2025282162A Pending JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025282162A Pending JP2026053635A (ja) 2020-04-23 2025-12-25 アルツハイマー病を治療するためのｒｈｏキナーゼ阻害剤の使用方法

Country Status (7)

Country Link
US (3) US12329761B2 (https=)
EP (1) EP4138842A4 (https=)
JP (2) JP2023523706A (https=)
CN (1) CN115996728A (https=)
CA (1) CA3175183A1 (https=)
MX (1) MX2022012957A (https=)
WO (1) WO2021216139A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
CN115998736B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Y-27632在特异性抑制幻觉作用中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501479A (ja) * 2006-08-10 2010-01-21 トランスレーショナル ジェノミクス リサーチ インスティテュート 学習および記憶を改善するための化合物
JP2011519972A (ja) * 2008-05-12 2011-07-14 アムネスティックス・インコーポレーテッド Ｒｈｏキナーゼ阻害のためのならびに学習及び記憶を改善するための化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
WO2006094072A2 (en) 2005-03-01 2006-09-08 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases
US9980972B2 (en) 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
US9481864B1 (en) * 2015-06-30 2016-11-01 University Of South Florida Conversion of non-neuronal cells into neurons
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
EP4232041A4 (en) 2020-10-22 2024-09-25 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20240423998A1 (en) * 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501479A (ja) * 2006-08-10 2010-01-21 トランスレーショナル ジェノミクス リサーチ インスティテュート 学習および記憶を改善するための化合物
JP2011519972A (ja) * 2008-05-12 2011-07-14 アムネスティックス・インコーポレーテッド Ｒｈｏキナーゼ阻害のためのならびに学習及び記憶を改善するための化合物

Also Published As

Publication number Publication date
EP4138842A1 (en) 2023-03-01
US20250268911A1 (en) 2025-08-28
CN115996728A (zh) 2023-04-21
MX2022012957A (es) 2022-11-09
JP2026053635A (ja) 2026-03-25
US20230302011A1 (en) 2023-09-28
US12329761B2 (en) 2025-06-17
WO2021216139A1 (en) 2021-10-28
EP4138842A4 (en) 2024-04-24
US20230190765A1 (en) 2023-06-22
CA3175183A1 (en) 2021-10-28
US11771704B1 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
JP2023530120A (ja) 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法
US11666583B2 (en) Methods of treating cortical dementia associated wandering
US20230263806A1 (en) Methods of treating proteinopathies
EP4232041A1 (en) Methods of treating 4-repeat tauopathies
EP4125910B1 (en) Rho kinase inhibitors for treating frontotemporal dementia
WO2022046158A1 (en) Methods of treating age-related cognitive decline
WO2022046160A1 (en) Methods of treating age-related cognitive decline

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826